CXCL2 and neoplasm: (A) Ki-67 positive AMs, (B) Cxcl2 expression in AMs, (C) Cd274 mRNA expression in Epcam+ tumor cells from lungs of control (normal) and tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks.